Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E MAP2K1 P124S |
Therapy | Selumetinib |
Indication/Tumor Type | melanoma |
Response Type | decreased response |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E MAP2K1 P124S | melanoma | decreased response | Selumetinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931). | 22197931 |
PubMed Id | Reference Title | Details |
---|---|---|
(22197931) | Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. | Full reference... |